证券代码：833819 证券简称：颖泰生物 公告编号：2024-042 北京颖泰嘉和生物科技股份有限公司 解除股权质押的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 一、 解除股权质押情况 二、 备查文件目录 （一）《质押协议》 （二）《解除质押登记证明》 （一） 本次解除股权质押基本情况 公司接到股东华邦生命健康股份有限公司的通知，股东华邦生命 健康股份有限公司本次解除股份质押 148,000,000 股，占其所持股份 25.99%，占公司总股本 12.07%。本次解质的股份中，0 股为有限售条 件股份，148,000,000 股为无限售条件股份，解质的股份已在中国结 算办理相关手续，解除日期为 2024 年 10 月 14 日。上述股份于 2021 年 8 月 18 日被质押，质押权人为中国进出口银行重庆分行。 （二） 剩余被质押股权的情况 截至公告披露日，公司股东华邦生命健康股份有限公司剩余被质 押的股份为 352,000,000 股，占其所持股份的 61.82%，占公司总股 本的 28. ...

证券代码：833819 证券简称：颖泰生物 公告编号：2024-041 北京颖泰嘉和生物科技股份有限公司 关于控股子公司获得农业转基因生物安全证书的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误 导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带法律 责任。 一、基本情况 2024 年 10 月 11 日，农业农村部公布了《2024 年农业转基因生 物安全证书（生产应用）批准清单》，北京颖泰嘉和生物科技股份有 限公司（以下简称"公司"）的控股子公司科稷达隆（北京）生物技术 有限公司（以下简称"科稷达隆"）研发的耐除草剂棉花 KJC017 获得 农业转基因生物安全证书（生产应用）。具体情况如下： | 审批编号 | 申报单位 | 项目名称 | | 有效期 | | | | 有效区域 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 农基安证字 | | 转 cp4epsps | 基因耐除 | | | | | | | | 科稷达隆（北京）生 | | | 2024 年 | 10 | 月 8 | 日至 | ...

证券代码：833819 证券简称：颖泰生物 公告编号：2024-040 北京颖泰嘉和生物科技股份有限公司 关于部分董事、高级管理人员增持股份计划公告 | | | | 宗交易 | 划公告 | 格 | 择 | | 展前景的 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | 之日起 | 机 | 增 | | 信心以及 | | | | | | 不超过 | 持 | | | 对公司投 | | | | | | 6 个月 | | | | 资价值的 | | | | | | | | | | 认可 | | 陈伯阳 | 不低于 | 不低于 | 集中竞 | 自增持 | 以 | 市 | 自有 | 基于对公 | | | 80,000 | 300,000 | 价或大 | 股份计 | 场 | 价 | 资金 | 司未来发 | | | | | 宗交易 | 划公告 | 格 | 择 | | 展前景的 | | | | | | 之日起 | 机 | 增 | | 信心以及 | | | | | | 不超过 | 持 | | | 对公司投 | | | | | | 6 个月 | | ...

| 日期 | 代码 | 简称 | 成交价 | 成交数量（股） | 买入营业部 | 卖出营业部 | | --- | --- | --- | --- | --- | --- | --- | | 2024-09- | | | | | 中国中金财富证券有 | 华泰证券股份有限公 | | 11 | 830799 | 艾融软件 | 8.3 | 600000 | 限公司北京北三环东 | 司郑州经三路证券营 | | | | | | | 路证券营业部 | 业部 | | 2024-09- | | | | | 中国中金财富证券有 | 华泰证券股份有限公 | | 11 | 830799 | 艾融软件 | 8.3 | 700000 | 限公司北京北三环东 | 司郑州经三路证券营 | | | | | | | 路证券营业部 | 业部 | | 2024-09- | | | | | 中国中金财富证券有 | 华泰证券股份有限公 | | 11 | 830799 | 艾融软件 | 8.3 | 800000 | 限公司北京北三环东 | 司郑州经三路证券营 | | | | | | | 路证券营业部 | 业部 | | 2024-09- | | | | | ...

| 日期 | 代码 | 简称 | 成交价 | 成交数量（股） | 买入营业部 | 卖出营业部 | | --- | --- | --- | --- | --- | --- | --- | | 2024-09- | 833819 | | | | 招商证券股份有限公 | 招商证券股份有限公 | | 10 | | 颖泰生物 | 1.68 | 850000 | 司北京车公庄西路证 | 司北京车公庄西路证 | | | | | | | 券营业部 | 券营业部 | | 2024-09- | | | | | 国海证券股份有限公 | 国海证券股份有限公 | | 10 | 920118 | 太湖远大 | 11.9 | 170000 | 司深圳福中三路营业 | 司深圳福中三路营业 | | | | | | | 部 | 部 | ...

| 日期 | 代码 | 简称 | 成交价 | 成交数量（股） | 买入营业部 | 卖出营业部 | | --- | --- | --- | --- | --- | --- | --- | | 2024-09- | | | | | 招商证券股份有限公 | 招商证券股份有限公 | | 09 | 833819 | 颖泰生物 | 1.69 | 850000 | 司北京车公庄西路证 | 司北京车公庄西路证 | | | | | | | 券营业部 | 券营业部 | | 2024-09- 09 | 835368 | 连城数控 | 14.5 | 655000 | 申万宏源证券有限公 司吉林分公司 | 申万宏源西部证券有 限公司霍尔果斯亚欧 | | | | | | | | 路证券营业部 | | 2024-09- 09 | 837592 | 华信永道 | 17.18 | 250000 | 广发证券股份有限公 司上海控江路营业部 | 中国中金财富证券有 限公司杭州教工路证 | | | | | | | | 券营业部 | ...

（一）（原告/上诉人）基本信息： 姓名或名称：龙口市泰和国际贸易有限公司 法定代表人/法定代理人/其他负责人：曲思辉 诉讼代理人及所属律所：尚未确定、尚未确定 （二）（被告/被上诉人）基本信息： 姓名或名称：烟台忠慧国际贸易有限公司（被告一） 法定代表人/法定代理人/其他负责人：孙慧艳 诉讼代理人及所属律所：尚未确定、尚未确定 其他信息：烟台忠慧国际贸易有限公司原名为"烟台福尔国际贸 易有限公司",系本案被告二前全资子公司，2019 年被告二处置被告 一全部股权。 证券代码：833819 证券简称：颖泰生物 公告编号：2024-039 北京颖泰嘉和生物科技股份有限公司关于全资子公司 涉及诉讼公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 一、本次重大诉讼事项受理的基本情况 收到应诉通知书的日期：2024 年 8 月 28 日 诉讼受理日期：2024 年 8 月 28 日 受理法院的名称：山东省龙口市人民法院 注：以上"诉讼受理日期"尚未确定，为实际收到应诉通知书的日期。 二、有关重大诉讼事项的基本 ...

证券代码：833819 证券简称：颖泰生物 公告编号：2024-034 会议的召集、召开和表决程序符合《中华人民共和国公司法》《公 司章程》及公司《监事会议事规则》的有关规定 （二）会议出席情况 会议应出席监事 3 人，出席和授权出席监事 3 人。 北京颖泰嘉和生物科技股份有限公司 第四届监事会第五次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别 及连带法律责任。 一、会议召开和出席情况 （一）会议召开情况 5.会议主持人：王剑 6.召开情况合法、合规、合章程性说明： 本议案无需提交股东大会审议。 （二）审议通过《关于 2024 年半年度募集资金存放与实际使用情况 的专项报告》 监事王剑因公务以通讯方式参与表决。 二、议案审议情况 1.会议召开时间：2024 年 8 月 16 日 2.会议召开地点：公司会议室 3.会议召开方式：现场会议与通讯会议相结合 4.发出监事会会议通知的时间和方式：2024 年 8 月 6 日以电话及电 子邮件的方式发出 （一）审议通过《2024 年半年度报告及摘要》 1.议案内容： ...

证券代码：833819 证券简称：颖泰生物 公告编号：2024-037 北京颖泰嘉和生物科技股份有限公司 关于 2024 年半年度募集资金存放与实际使用情 况的专项报告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 根据中国证监会发布的《上市公司监管指引第 2 号——上市公司 募集资金管理和使用的监管要求（2022 年修订）》和北京证券交易所 颁布的《北京交易所股票上市规则（试行）》等有关规定，按照北京 颖泰嘉和生物科技股份有限公司（以下简称"公司"）制定的《募集 资金管理制度》相关要求，公司董事会编制了截至 2024 年 6 月 30 日 募集资金存放与实际使用情况的专项报告。 一、募集资金基本情况 （一）募集资金金额及到账时间 资金净额为人民币 511,992,868.50 元，本次实际募集资金净额考 虑 可 抵 扣 增 值 税 人 民 币 1,868,328.20 元后为人民币 513,861,196.70 元。 四川华信（集团）会计师事务所（特殊普通合伙）对公司向不 特定合格投资者公开发行股票 ...

Financial Performance - The company's operating revenue for the first half of 2024 was approximately ¥2.88 billion, a decrease of 2.57% compared to ¥2.95 billion in the same period last year[14]. - The gross profit margin dropped to 12.46%, down from 19.63% in the previous year[14]. - The net profit attributable to shareholders was a loss of approximately ¥79.38 million, a decline of 152.88% compared to a profit of ¥150.13 million in the same period last year[14]. - The net profit after deducting non-recurring gains and losses was a loss of approximately ¥89.12 million, down 157.93% from a profit of ¥153.84 million last year[14]. - The weighted average return on net assets based on net profit attributable to shareholders was -1.39%, compared to 2.50% in the previous year[14]. - The basic earnings per share decreased to -0.06, a drop of 150.00% from 0.12 in the same period last year[14]. - Total assets increased by 0.73% to ¥12,734,196,624.68 compared to the previous year[15]. - Total liabilities rose by 4.82% to ¥7,183,918,627.08, resulting in a debt-to-asset ratio of 56.41%[15]. - Net profit decreased by 156.38% to -¥79,384,075.67, compared to a profit of ¥150,131,634.59 in the same period last year[23]. - Revenue declined by 2.57% to ¥2,878,968,888.16, down from ¥2,954,829,186.08 year-on-year[23]. - The company reported non-recurring gains of ¥9,738,845.55 after tax, with total non-recurring gains amounting to ¥11,163,721.00[18]. - The company reported a total of 1,100,000,000.00 CNY in external guarantees, with a balance of 760,483,000.00 CNY[63]. - The company reported sales of products and services to related parties amounting to 601,100,000.00 CNY, with actual sales at 112,065,102.56 CNY[64]. Market and Operational Strategies - The company plans to focus on expanding the market, serving customers, controlling costs, and enhancing operational efficiency in response to industry challenges[3]. - The company plans to enhance market strategies and optimize customer structure to improve sales channels and market share in 2024[23]. - The company aims to leverage existing resources and extend business opportunities to ensure stable operations[23]. - The company is committed to fulfilling its social responsibilities, enhancing its engagement with stakeholders including investors, employees, and the community[42]. - The company is focusing on market expansion and new product development to drive future growth[91]. Research and Development - Research and development expenses decreased by 9.46% to CNY 85,066,760.84, compared to CNY 93,956,787.89 in the same period last year[30]. - The company is committed to increasing R&D investment and improving management levels to meet the standards for high-tech enterprise re-certification[57]. Environmental and Social Responsibility - The company continues to support rural revitalization efforts, contributing to local infrastructure and charitable initiatives[41]. - The company aims to achieve a balance between sustainable development and ecological protection, actively working towards carbon neutrality goals[43]. - The company actively engages in environmental protection, optimizing processes to reduce energy consumption and pollutant emissions[43]. - The company has established a talent development system, providing various training courses to enhance employee skills and competencies[43]. - The company has implemented a rigorous air pollution control system, including RTO technology for exhaust gas treatment[50]. Financial Position and Assets - The total current assets increased to ¥4,981,959,802.47 from ¥4,842,717,364.14, showing an increase of approximately 2.9%[81]. - The total equity attributable to shareholders decreased to ¥5,553,421,047.45 from ¥5,785,267,304.60, a decline of about 4.00%[84]. - The company has restricted assets totaling 1,328,911,355.35, accounting for 10.44% of total assets, primarily used as collateral for daily operational loans[68]. - The total number of ordinary shares is 1,225,800,000, with 25,303 shareholders[69]. - The company has a total of 59.62 million in foreign currency deposits, which decreased from 68.04 million at the beginning of the year[196]. Governance and Management - The board of directors consists of 9 members, while the supervisory board has 3 members, ensuring a balanced governance structure[75]. - The company appointed Liu Xiaoliang as the new General Manager, effective from July 10, 2024, to oversee daily operations[80]. - The company has no changes in the positions of the chairman, general manager, or independent directors during the reporting period[77]. Compliance and Risk Management - The company strictly adheres to relevant laws and regulations, ensuring accurate and timely information disclosure to protect investor interests[43]. - The company has established an emergency response system for environmental incidents, with regular drills and risk assessment reports completed and filed with local environmental authorities[52]. - The company has implemented a self-monitoring scheme for environmental compliance, with monitoring results meeting relevant discharge standards and publicly disclosed on national platforms[53]. - The company has established a risk-oriented internal management system to address the increasing environmental protection requirements imposed by the government[58]. Shareholder and Equity Information - The largest shareholder, Huabang Life Health Co., Ltd., holds 569,438,458 shares, representing 46.45% of total shares[70]. - A total of 500,000,000 shares held by Huabang Life Health Co., Ltd. are pledged, while 46,968,250 shares held by Zhejiang Xin'an Chemical Group Co., Ltd. are judicially frozen[72]. - The company has provided guarantees to related parties, with a total guarantee amount of 3,197,500,000.00 CNY[65]. Taxation and Financial Regulations - The applicable corporate income tax rate for the company and its subsidiaries is 15%, as they are recognized as high-tech enterprises, which may be affected by changes in tax policies[57]. - The company expects certain subsidiaries to qualify for small and micro enterprise tax reductions, which will affect the income tax expenses for the fiscal year 2024[194]. Accounting Policies and Financial Reporting - The company uses the accrual basis of accounting, ensuring that financial information accurately reflects its financial position and performance[128]. - The company recognizes deferred tax assets and liabilities based on the difference between the tax base and the carrying amount of assets and liabilities, confirming deferred tax liabilities for taxable temporary differences[182]. - The company has not changed its accounting policies or estimates compared to the previous year's financial statements[111].